ALLO Research and Charts

ALLO - Allogene Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-06 (Delayed quote data 2025-01-03)

Last 2.16	Change ⇓ -0.04 (-1.82%)	Volume 2,516,426
	Open 2.21	High 2.27	Low 2.14

8EMA (Daily) 2.12	40EMA (Daily) 2.25	50EMA (Daily) 2.30	STO (Daily) 70.441	MACD Hist (Daily) 0.071
8EMA (Weekly) 2.209	40EMA (Weekly) 2.74	50EMA (Weekly) 2.96	STO (Weekly) 14.843	MACD Hist (Weekly) -0.048


Company Profile
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.